Mumbai, India-based Indoco Remedies will manufacture eight APIs for DSM's pharmaceutical products business unit. DSM said the alliance will leverage Indoco's product development and cGMP manufacturing capabilities and DSM's market access. Additionally DSM said the deal fits with its global expansion plans.
Hindu Business Line
Tuesday, 31 January 2012
Indian manufacturing pact for DSM
Wednesday, 25 January 2012
Lonza results miss estimates, fires CEO
Lonza has reported its full year 2011 revenues before the Arch acquisition of CHF2.5m, up 5% in constant exchange rates, missing analyst estimates. The company also announced that its CEO, Stefan Borgas, would be leaving the company with immediate effect. Lonza's share price fell 13% on the day the results were announced.
Lonza said its custom manufacturing continued to benefit from demand for outsourcing from pharmaceutical and biotech companies. The company said its capacity utilisation rate for small molecules was 78% and for biological molecules was 87% excluding the recently opened Singapore facility and it had increased the number of contracts it had signed.
Outsourcing Pharma
Strong year for Albemarle
Albemare reported a strong Q4 and full year 2011 for its fine chemistry business unit. Sales in Q4 rose 36% to $209m and income 62% to $43m. For the full year the unit reported record sales of$750m up 32% and income doubles to $140m. The company said that the unit is set for another strong year in 2012.
Seeking Alpha
Monday, 23 January 2012
Thursday, 19 January 2012
Avecia Biotechnology plans acquisition
Avecia Biotechnology has identified a possible acquisition target that would expand its capabilities. Company President Detlef Rethage said it has chosen a company in the fill and finish business. Avecia has not indicated when the acquisition would be completed.
Mass High Tech
AMRI UK site receives GMP certificate
AMRI’s Holywell, UK, manufacturing facility has received a GMP certificate following an inspection in October 2011. The site also passes a US FDA audit in June 2011. AMRI said the former Excelsyn facility can now produce registered intermediates and active ingredients for use in humans and expands the range of projects that it can now conduct at this facility.
AMRI
Tuesday, 17 January 2012
Molecular Profiles to expand cGMP capacity
Molecular Profiles is adding a new £9m manufacturing facility at its Nottingham, UK, site. The new facility, which is due to open later this year, will add 3000m2 of space and provide six new GMP suites, new laboratories and a clinical packing suite. It is designed to enable flexibility of use and the manufacture of highly potent compounds up to OEB 4 level.
InPharm
Carbogen Amcis acquires Creapharm
Dishman Pharmaceuticals subsidiary Carbogen Amcis has acquired Creapharm Parenterals for an undisclosed sum. The business, which will be renamed Carbogen Amcis SAS, adds complimentary formulation and lyophilisation services as well as sterile GMP-standard capabilities for the rapid supply of medicines, including highly potent compounds for preclinical and clinical trials to Carbogen Amcis.
Pharma Times
Monday, 16 January 2012
Tuesday, 10 January 2012
Future of AMRI's Hungary facility in doubt
AMRI is considering options for its custom research and manufacturing facility in Budapest, Hungary. The company said the site had been losing money over the last two years and the company is considering transferring the activities to other sites.
Outsourcing Pharma
Monday, 9 January 2012
Thursday, 5 January 2012
Subscribe to:
Posts (Atom)
